EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, US Stem Cell's Enterprise Value is $0.00 Mil.
US Stem Cell's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.31 Mil. Therefore, US Stem Cell's EV-to-FCF for today is 0.00.
The historical rank and industry rank for US Stem Cell's EV-to-FCF or its related term are showing as below:
USRM's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 8.405 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for US Stem Cell's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of US Stem Cell's EV-to-FCF
For the Biotechnology subindustry, US Stem Cell's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where US Stem Cell's EV-to-FCF falls into.
US Stem Cell EV-to-FCF Calculation
US Stem Cell's EV-to-FCF for today is calculated as:
US Stem Cell's current Enterprise Value is $0.00 Mil.
US Stem Cell's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
US Stem Cell (OTCPK:USRM) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
US Stem Cell's PE Ratio for today is calculated as:
US Stem Cell's share price for today is $0.0001.
US Stem Cell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.005.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
US Stem Cell EV-to-FCF Related Terms
Thank you for viewing the detailed overview of US Stem Cell's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
USRM has been successfully added to your 